Efficacy and safety of anlotinib hydrochloride combined with nivolumab in the treatment of advanced upper gastrointestinal tumor as second-line or later-line therapy: The results of gastric cancer cohort

被引：0
|
作者：
Cui, Yuehong
Yu, Yiyi
Wu, Jing
Li, Qian
Liang, Li
Wang, Yan
Yu, Shan
Liu, Tianshu
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Med Oncol, Shanghai, Peoples R China
[2] Fudan Univ, Zhongshan Hosp, Dept Oncol, Canc Ctr, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16015
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of anlotinib as a later-line treatment for advanced colorectal cancer.
    Song, Yang
    Liu, Lili
    Min, Jie
    You, Xianghui
    Yang, Xue
    Zhang, Feng
    Huang, Xiaofeng
    Liao, Chenggong
    Shi, Hong
    Su, Haichuan
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 194 - 194
  • [2] Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
    Hiroki Ishihara
    Toshio Takagi
    Tsunenori Kondo
    Hironori Fukuda
    Hidekazu Tachibana
    Kazuhiko Yoshida
    Junpei Iizuka
    Hirohito Kobayashi
    Masayoshi Okumi
    Hideki Ishida
    Kazunari Tanabe
    International Journal of Clinical Oncology, 2020, 25 : 705 - 712
  • [3] Comparable efficacy and safety between second-line and later-line nivolumab therapy for metastatic renal cell carcinoma
    Ishihara, Hiroki
    Takagi, Toshio
    Kondo, Tsunenori
    Fukuda, Hironori
    Tachibana, Hidekazu
    Yoshida, Kazuhiko
    Iizuka, Junpei
    Kobayashi, Hirohito
    Okumi, Masayoshi
    Ishida, Hideki
    Tanabe, Kazunari
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (04) : 705 - 712
  • [4] Efficacy and adverse reactions of apatinib as second-line or later-line treatment in advanced lung cancer
    Tao Ren
    Yan Wu
    Oncology and Translational Medicine, 2021, 7 (04) : 160 - 164
  • [5] Synergistic effect of additional anlotinib and immunotherapy as second-line or later-line treatment in pancreatic cancer: A retrospective cohort study
    Qin, Boyu
    Xiong, Qi
    Xin, Lingli
    Li, Ke
    Shi, Weiwei
    Song, Qi
    Sun, Qiong
    Shao, Jiakang
    Zhang, Jing
    Zhao, Xiao
    Liu, Jinyu
    Wang, Jinliang
    Yang, Bo
    CANCER INNOVATION, 2024, 3 (04):
  • [6] Nivolumab monotherapy in second- or later-line treatment for advanced or recurrent esophageal cancer
    Miyajima, Saori
    Tsuji, Kunihiro
    Kito, Yosuke
    ANNALS OF ONCOLOGY, 2023, 34 : S1436 - S1436
  • [7] EFFICACY ANALYSIS OF APATINIB COMBINED WITH CHEMOTHERAPY IN THE TREATMENT OF ADVANCED SECOND-LINE GASTRIC CANCER
    Fan, Cuizhen
    Guo, Hongqiang
    Chu, Yuping
    An, Guangyu
    ACTA MEDICA MEDITERRANEA, 2022, 38 (01): : 1 - 5
  • [8] Efficacy and safety of anlotinib combined with vinorelbine as second-line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort
    Li, Yonghong
    Li, Wei
    Liu, Yirui
    Peng, Yi
    Tang, Jing
    Li, Xiaobing
    MOLECULAR AND CLINICAL ONCOLOGY, 2025, 22 (02)
  • [9] Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
    Jiang, Man
    Zhang, Chuantao
    Hu, Yabin
    Li, Tianjun
    Yang, Guangjie
    Wang, Guanqun
    Zhu, Jingjuan
    Shao, Changfeng
    Hou, Helei
    Zhou, Na
    Liu, Kewei
    Zhang, Xiaochun
    ONCOLOGIST, 2022, 27 (11): : E856 - E869
  • [10] Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Shi, Q.
    Xie, Q.
    Lin, H.
    He, Y.
    Zheng, X.
    Zhou, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1568
12345